Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2007; 132(19): 1048-1052
DOI: 10.1055/s-2007-979380
DOI: 10.1055/s-2007-979380
Prinzip & Perspektive | Review article
Endokrinologie© Georg Thieme Verlag KG Stuttgart · New York
Adipokine und Lipidstoffwechsel bei Typ-2-Diabetes
Adipokines and lipid metabolism in type 2 diabetesFurther Information
Publication History
eingereicht: 12.2.2007
akzeptiert: 28.3.2007
Publication Date:
03 May 2007 (online)

Schlüsselwörter
Adipokine - Lipide - Diabetes mellitus Typ 2 - metabolisches Syndrom
Key words
Adipokines - lipids - diabetes mellitus type 2 - metabolic syndrome
Literatur
- 1
Adiels M, Olofsson S O. et al .
Diabetic dyslipidaemia.
Curr Opin Lipidol.
2006;
17
238-246
MissingFormLabel
- 2
Baar R A, Dingfelder C S. et al .
Investigation of in vivo fatty acid metabolism in AFABP/aP2(-/-) mice.
Am J Physiol Endocrinol Metab.
2005;
288
E187-E193
MissingFormLabel
- 3
Colhoun H M, Betteridge D J. et al .
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes
in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled
trial.
Lancet.
2004;
364
685-696
MissingFormLabel
- 4
Dobbins R L, Szczepaniak L S. et al .
Chemical sympathectomy alters regulation of body weight during prolonged ICV leptin
infusion.
Am J Physiol Endocrinol Metab.
2003;
284
E778-E787
MissingFormLabel
- 5
Erikstrup C O, Mortensen H. et al .
Retinol-binding protein 4 and insulin resistance.
N Engl J Med.
2006;
355
1393-1394
MissingFormLabel
- 6
Evans J M, Wang J, Morris A D.
Comparison of cardiovascular risk between patients with type 2 diabetes and those
who had had a myocardial infarction: cross sectional and cohort studies.
Brit Med J.
2002;
324
939-942
MissingFormLabel
- 7
Executive Summary of The Third Report of The National Cholesterol Education Program
(NCEP) .
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In
Adults (Adult Treatment Panel III).
J Am Med Assoc.
2001;
285
2486-2497
MissingFormLabel
- 8
Friedman J M.
The function of leptin in nutrition, weight, and physiology.
Nutr Rev.
2002;
60
S1-14
MissingFormLabel
- 9
Graham T E, Yang Q. et al .
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.
N Engl J Med.
2006;
354
2552-2563
MissingFormLabel
- 10
Grundy S M, Cleeman J I. et al .
Implications of recent clinical trials for the National Cholesterol Education Program
Adult Treatment Panel III guidelines.
Circulation.
2004;
110
227-239
MissingFormLabel
- 11
Haffner S M, Lehto S. et al .
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic
subjects with and without prior myocardial infarction.
N Engl J Med.
1998;
339
229-234
MissingFormLabel
- 12
Havel P J.
Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid
metabolism.
Diabetes.
2004;
53
S143-151
MissingFormLabel
- 13
Kadowaki T, Yamauchi T.
Adiponectin and adiponectin receptors.
Endocr Rev.
2005;
26
439-451
MissingFormLabel
- 14
McTernan P G, Kusminski C M. et al .
Resistin.
Curr Opin Lipidol.
2006;
17
170-175
MissingFormLabel
- 15
MRC/BHF .
Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk
individuals: a randomised placebo-controlled trial.
Lancet.
2004;
360
7-22
MissingFormLabel
- 16
Oral E A, Simha V. et al .
Leptin-replacement therapy for lipodystrophy.
N Engl J Med.
2002;
346
570-578
MissingFormLabel
- 17
Rothenbacher D, Brenner H. et al .
Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk
markers.
Eur Heart J.
2005;
26
1640-1646
MissingFormLabel
- 18
Sato N, Kobayashi K. et al .
Adenovirus-mediated high expression of resistin causes dyslipidemia in mice.
Endocrinology.
2005;
146
273-279
MissingFormLabel
- 19
Schneider J G, von Eynatten M. et al .
Low plasma adiponectin levels are associated with increased hepatic lipase activity
in vivo.
Diabetes Care.
2005;
28
2181-2186
MissingFormLabel
- 20
Shetty G K, Economides P A. et al .
Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory
markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes.
Diabetes Care.
2004;
27
2450-2457
MissingFormLabel
- 21
Smith J, Al-Amri M. et al .
Visfatin concentration in Asian Indians is correlated with high density lipoprotein
cholesterol and apolipoprotein A1.
Clin Endocrinol.
2006;
65
667-672
MissingFormLabel
- 22
Stejskal D, Karpisek M.
Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic
syndrome?.
Eur J Clin Invest.
2006;
36
621-625
MissingFormLabel
- 23
Stephens J M, Vidal-Puig A J.
An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed,
illusive cytokine that is regulated in obesity.
Curr Opin Lipidol.
2006;
17
128-131
MissingFormLabel
- 24
Takashima N, Tomoike H. et al .
Retinol-binding protein 4 and insulin resistance.
N Engl J Med.
2006;
355
1392
MissingFormLabel
- 25
von Eynatten M, Hamann A. et al .
Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia,
and heart failure in patients with coronary heart disease.
Clin Chem.
2006;
52
853-859
MissingFormLabel
- 26
von Eynatten M, Schneider J G. et al .
Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent
of systemic inflammation and insulin resistance.
Diabetes Care.
2004;
27
2925-2929
MissingFormLabel
- 27
von Eynatten M, Schneider J G.
The role of adiponectin in atherosclerosis: do lipids tipp the scales?.
Future Cardiol.
2005;
1
775-784
MissingFormLabel
- 28
Yamauchi T, Kamon J. et al .
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating
AMP-activated protein kinase.
Nat Med.
2002;
8
1288-1295
MissingFormLabel
- 29
Yu Y H, Ginsberg H N.
Adipocyte signaling and lipid homeostasis: sequelae of insulin resistant adipose tissue.
Circ Res.
2005;
96
1042-1052
MissingFormLabel
Dr. Maximilian von Eynatten
Klinikum rechts der Isar, Innere Medizin II, Abteilung Nephrologie
Ismaningerstraße 22
81675 München
Phone: 089/41404969
Fax: 089/41404741
Email: maximilian.eynatten@lrz.tum.de